Skip to main content

Table 2 Barriers to the dissemination and implementation of the results of the Magpie Trial results by country group*

From: Translating research into policy and practice in developing countries: a case study of magnesium sulphate for pre-eclampsia

Barrier Number of countries from which at least one representative gave a response
  Low and lower-middle income countries (n = 13#) Upper-middle income countries (n = 3#) High-income countries (n = 8#) Total
Political barriers 8 2 2 12
Lack of information or awareness regarding magnesium sulphate 6 2 1 9
Costs of treatment 5 2 1 8
Lack of availability of personnel and hospitals 5 1 1 7
Lack of support from public authorities 4 1 2 7
Lack of availability of magnesium sulphate 5 0 1 6
Lack of clinical practice guidelines 1 1 3 5
Magnesium sulphate not registered for treatment of eclampsia/pre-eclampsia 1 1 0 2
  1. * 17 respondents either did not reply or had illegible responses to this question.
  2. # Total number of countries in this group.